We are excited to attend the 22nd Drug Discovery Strategic Summit from October 21st - 22nd, in Millbrae, CA. Join us to connect with pharma and biotech professionals, and to stay up to date on the latest industry trends. Visit our team at booth #10 to learn more about our target-humanized and disease mouse models supporting target validation, in vivo pharmacology and preclinical drug discovery.
What is the 22nd Drug Discovery Strategic Summit?
The 22nd Drug Discovery Strategic Summit is a premier, invite-only event that offers a focused setting for executives, innovators, and stakeholders to examine the latest scientific advances and tools that are shaping the future of drug discovery. The program combines expert presentations with 1:1 networking meetings, encouraging attendees to exchange ideas and explore potential partnerships.
Event Overview
Date: October 21st - 22nd, 2026
Venue: The Westin San Francisco Airport, 1 Old Bayshore Hwy, Millbrae, CA 94030
Booth: 10
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
